2950-3280

Blood Neoplasia

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 266 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact266 DOIs
2

Deposit reference lists for 21 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact21 DOIs
3

Attach ORCID iDs across 5 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact5 DOIs

DOIs for this ISSN

Showing the top 5 of 266 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Real-world outcomes of newly diagnosed AML treated with vene… (10.1016/j.bneo.2024.100017)
Abstract
40.84 42
2 Improved survival with daratumumab-CyBorD compared with CyBo… (10.1016/j.bneo.2025.100092)
Abstract
31.97 18
3 Venetoclax and hypomethylating agents in octogenarians and n… (10.1016/j.bneo.2024.100016)
Abstract
31.38 17
4 Ibrutinib and venetoclax in combination for chronic lymphocy… (10.1016/j.bneo.2024.100034)
Abstract
29.40 14
5 Comparison of TP53 mutations in myelodysplasia and acute leu… (10.1016/j.bneo.2024.100004)
Abstract
28.65 13
6 Real-world experience with targeted therapy in patients with… (10.1016/j.bneo.2024.100023)
Abstract
27.85 12
7 Addition of navitoclax to ruxolitinib for patients with myel… (10.1016/j.bneo.2024.100056)
Abstract
27.85 12
8 Devimistat plus chemotherapy vs chemotherapy alone for older… (10.1016/j.bneo.2024.100009)
Abstract
26.98 11
9 CD38-CAR human NK cells in combination with ATRA enhance cyt… (10.1016/j.bneo.2024.100032)
Abstract
26.98 11
10 KIR3DL1-HLA-Bw status in CML is associated with achievement… (10.1016/j.bneo.2024.100001)
Abstract
25.00 9
11 Loss of p53 impairs death receptor expression and confers re… (10.1016/j.bneo.2024.100060)
Abstract
25.00 9
12 A novel application of XPO1 inhibition for the treatment of… (10.1016/j.bneo.2024.100010)
Abstract
23.86 8
13 A phase 1 study of IO-202, an anti-LILRB4 antibody, in chron… (10.1016/j.bneo.2025.100126)
Abstract
23.86 8
14 Central role of the mTORC1 pathway in glucocorticoid activit… (10.1016/j.bneo.2024.100015)
Abstract
22.58 7
15 Impact of ibrutinib dose adjustment on TTNT in first-line CL… (10.1016/j.bneo.2024.100022)
Abstract
22.58 7
16 JAK1/2 inhibitor ruxolitinib for the treatment of systemic c… (10.1016/j.bneo.2024.100053)
Abstract
22.58 7
17 Prospective performance of the IWG-2023 criteria and IPSS-M… (10.1016/j.bneo.2024.100008)
Abstract
21.13 6
18 A phase 1 study adding pitavastatin to venetoclax therapy in… (10.1016/j.bneo.2024.100036)
Abstract
21.13 6
19 Real-world characteristics, treatment patterns, and outcomes… (10.1016/j.bneo.2024.100047)
Abstract
21.13 6
20 Development and characterization of a low-affinity humanized… (10.1016/j.bneo.2024.100048)
Abstract
21.13 6
21 Race and age disparities in randomized trials of acute myelo… (10.1016/j.bneo.2025.100070)
Abstract
21.13 6
22 Response and outcomes of patients with IDH1/2- mutated accel… (10.1016/j.bneo.2025.100089)
Abstract
21.13 6
23 Belantamab mafodotin in patients with relapsed/refractory mu… (10.1016/j.bneo.2025.100103)
Abstract
21.13 6
24 Minimal residual disease measurement in blood by mass spectr… (10.1016/j.bneo.2025.100124)
Abstract
21.13 6
25 Real-world comparison of daratumumab-based regimens in relap… (10.1016/j.bneo.2024.100003)
Abstract
19.45 5
26 Instructive interaction between myelodysplastic hematopoiesi… (10.1016/j.bneo.2024.100021)
Abstract
19.45 5
27 Safety landscape of bispecific antibody therapy in non-Hodgk… (10.1016/j.bneo.2024.100061)
Abstract
19.45 5
28 A feedforward loop between ACLY and MYC supports T-ALL progr… (10.1016/j.bneo.2025.100069)
Abstract
19.45 5
29 Real-world treatment patterns and clinical outcomes in patie… (10.1016/j.bneo.2025.100080)
Abstract
19.45 5
30 Dose escalation study of the HLA-A2-WT1 CD3 bispecific antib… (10.1016/j.bneo.2025.100110)
Abstract
19.45 5
31 Long-term remission with allogeneic transplant in patients w… (10.1016/j.bneo.2024.100007)
Abstract
17.47 4
32 Response-guided first-line therapy and treatment of relapse… (10.1016/j.bneo.2024.100018)
Abstract
17.47 4
33 T-cell lymphoblastic lymphoma compared with T-cell acute lym… (10.1016/j.bneo.2024.100029)
Abstract
17.47 4
34 Lenalidomide, ixazomib, or daratumumab maintenance therapy i… (10.1016/j.bneo.2024.100042)
Abstract
17.47 4
35 Phase 1b study of the anti-CD38 antibody mezagitamab in pati… (10.1016/j.bneo.2024.100043)
Abstract
17.47 4
36 Single-cell and spatial characterization of plasmablast-like… (10.1016/j.bneo.2024.100058)
Abstract
17.47 4
37 Risk factors and clinical impact of cytomegalovirus DNAemia… (10.1016/j.bneo.2025.100097)
Abstract
17.47 4
38 Activity of STAMP inhibitors in ABL2 rearranged acute lympho… (10.1016/j.bneo.2025.100109)
Abstract
17.47 4
39 NAMPT haploinsufficiency is a collateral lethal therapeutic… (10.1016/j.bneo.2025.100119)
Abstract
17.47 4
40 Beat AML genetic risk stratification model in a cohort of ol… (10.1016/j.bneo.2025.100125)
Abstract
17.47 4
41 Real-world outcomes with ibrutinib in relapsed or refractory… (10.1016/j.bneo.2025.100128)
Abstract
17.47 4
42 Saliva as a feasible alternative to blood for interrogation… (10.1016/j.bneo.2024.100012)
Abstract
15.05 3
43 The landscape of rare genetic variants in familial Waldenstr… (10.1016/j.bneo.2024.100013)
Abstract
15.05 3
44 Functional multiomics reveals genetic and pharmacologic regu… (10.1016/j.bneo.2024.100025)
Abstract
15.05 3
45 Targeting SLFN11-regulated pathways restores chemotherapy se… (10.1016/j.bneo.2024.100037)
Abstract
15.05 3
46 Intensive chemotherapy after hypomethylating agent and venet… (10.1016/j.bneo.2024.100038)
Abstract
15.05 3
47 Clinical and pathological features of pediatric peripheral T… (10.1016/j.bneo.2024.100039)
Abstract
15.05 3
48 Outcomes for high-risk defining events in follicular lymphom… (10.1016/j.bneo.2024.100044)
Abstract
15.05 3
49 Enitociclib, a selective CDK9 inhibitor: in vitro and in viv… (10.1016/j.bneo.2024.100050)
Abstract
15.05 3
50 Low platelet counts and low CD4/CD8 ratios at apheresis incr… (10.1016/j.bneo.2024.100051)
Abstract
15.05 3